AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6235082 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 27
Study 31397255 — intervention group
Group type: COMPARATOR
Intervention: High-Definition Transcranial Direct Current Stimulation (HD-tDCS)
Number of subjects: 22
Study 31397255 — intervention group
Group type: COMPARATOR
Intervention: Intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 22
Study 31397255 — intervention group
Group type: COMPARATOR
Intervention: Prolonged Continuous Theta Burst Stimulation (ProcTBS)
Number of subjects: 22
Study 31397255 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 22
Study 31397255 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided attention task
Number of subjects: 22
Study 31397255 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory maintenance task
Number of subjects: 22
Study 30265045 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy-Trauma (IPT-T)
Number of subjects: 162
Study 30265045 — intervention group
Group type: COMPARATOR
Intervention: Clinic Psychotherapy (CP)
Number of subjects: 162
Study 26885819 — intervention group
Group type: EXPERIMENTAL
Intervention: Amyloid PET imaging (florbetapir PET scanning)
Number of subjects: 278
Study 25173484 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA.HIVA vaccine
Number of subjects: 73
Study 25173484 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 73
Study 22300892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous administration of 12 million units (MU) IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Number of subjects: 30
Study 22300892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous administration of 9 MU IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Number of subjects: 30
Study 22300892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous administration of 6 MU IFN‐α2b daily with ribavirin (1,000‐1,600 mg) for 48 weeks
Number of subjects: 30
Study 22300892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous administration of IFN‐α2b with ribavirin
Number of subjects: 30
Study 22300892 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous administration of IFN‐α2b
Number of subjects: 30
Study 20554319 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 20211
Study 20554319 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20211
Study 18523583 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 KKW exercise training (4 kcal/kg/week)
Number of subjects: 373
Study 18523583 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 KKW exercise training (8 kcal/kg/week)
Number of subjects: 373
Study 18523583 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 KKW exercise training (12 kcal/kg/week)
Number of subjects: 373
Study 18523583 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 373
Study 16011678 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimator (MLE) for treatment assignment
Number of subjects: 0
Study 16011678 — intervention group
Group type: EXPERIMENTAL
Intervention: MLE for normal outcomes
Number of subjects: 0
Study 16011678 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from a trial comparing two antipsychotics
Number of subjects: 0
Study 12131074 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control measures including feedback on terminal digit preference
Number of subjects: 0
Study 12131074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups
Number of subjects: 0
Study 10360857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 60
Study 10360857 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study 7573997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine infusion to increase systolic blood pressure by 20%
Number of subjects: 1
Study 7573997 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 1
Study 1659173 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT) only
Number of subjects: 149
Study 1659173 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation Therapy + Chemotherapy (RT + Chemo)
Number of subjects: 149
Study 1659173 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation Therapy + Chemotherapy + Misonidazole (RT + Chemo/Miso)
Number of subjects: 149
Study 6803911 — intervention group
Group type: EXPERIMENTAL
Intervention: Pepsi-Cola
Number of subjects: 10
Study 6803911 — intervention group
Group type: COMPARATOR
Intervention: Soda water
Number of subjects: 10
Study 6803911 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 10
Study 31567485 — intervention group
Group type: EXPERIMENTAL
Intervention: Persons with Parkinson's disease
Number of subjects: 100
Study 31567485 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 28783867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 400 mg miconazole administered on 3 consecutive evenings during treatment on days 9-11.
Number of subjects: 52
Study 28783867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 100 mg clindamycin administered on 3 consecutive evenings during treatment on days 9-11.
Number of subjects: 52
Study 28783867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with 75 mg nonoxynol-9 administered on 3 consecutive evenings during treatment on days 9-11.
Number of subjects: 52
Study 28783867 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal ring (IVR) releasing 1050 μg ATZ per day and 40 μg LNG per day with tampon co-usage performed on days 20-23.
Number of subjects: 52
Study 27314120 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-on-2 (FO2) implants
Number of subjects: 40
Study 27314120 — intervention group
Group type: COMPARATOR
Intervention: Fixed-on-3 (FO3) implants
Number of subjects: 40
Study 25906603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya (SK)
Number of subjects: 60
Study 25906603 — intervention group
Group type: EXPERIMENTAL
Intervention: Prana-Yoga (PY)
Number of subjects: 60
Study 25906603 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22678323 — intervention group
Group type: EXPERIMENTAL
Intervention: Gasless video-assisted unilateral anterior chest wall approach
Number of subjects: 77
Study 22678323 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 77
Study 20430504 — intervention group
Group type: EXPERIMENTAL
Intervention: Single noncompression miniplate fixed at the superior border of the mandible (Group I)
Number of subjects: 54
Study 20430504 — intervention group
Group type: COMPARATOR
Intervention: Two noncompression miniplates (one at the superior border and one at the lateral aspect of the mandible) (Group II)
Number of subjects: 54
Study 17608932 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (comprehensive assessment visits at baseline and two, four and six months post randomisation)
Number of subjects: 176
Study 17608932 — intervention group
Group type: COMPARATOR
Intervention: Minimal follow-up (abbreviated assessment at baseline and full assessment at six months)
Number of subjects: 176
Study 17608932 — intervention group
Group type: COMPARATOR
Intervention: Carer quality of life
Number of subjects: 176
Study 15824055 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer coaching sessions with educational resources for GPs and patients
Number of subjects: 277
Study 11993095 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor AF2 (500 mg i.v., given at days 0‐3, 7‐10 and 11‐14)
Number of subjects: 106
Study 11993095 — intervention group
Group type: COMPARATOR
Intervention: Control group (without Factor AF2)
Number of subjects: 106
Study 11993095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without Factor AF2)
Number of subjects: 106
Study 10220741 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) therapy
Number of subjects: 180
Study 7532708 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor, 10 micrograms/kg intravenously, administered within 24 hours of birth and at 24-hour intervals for a maximum of three doses if neutropenia persisted
Number of subjects: 9
Study 2214101 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (275 mg of caffeine)
Number of subjects: 22
Study 110211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator
Number of subjects: 16
Study 110211 — intervention group
Group type: COMPARATOR
Intervention: Membrane oxygenator
Number of subjects: 16
Study 110211 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 16
Study 110211 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative day 14
Number of subjects: 16
Study 110211 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative day 7
Number of subjects: 16
Study 31438535 — intervention group
Group type: EXPERIMENTAL
Intervention: BA-ALKplaBCAA&TCM
Number of subjects: 31
Study 31438535 — intervention group
Group type: COMPARATOR
Intervention: ALK-BAplaBCAA&TCM
Number of subjects: 31
Study 27328681 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose (60g in 500mL water)
Number of subjects: 9
Study 27328681 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (60g in 500mL water)
Number of subjects: 9
Study 27328681 — intervention group
Group type: COMPARATOR
Intervention: Fructose (60g in 500mL water)
Number of subjects: 9
Study 26727778 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release of posterior knee clearance during total knee arthroplasty
Number of subjects: 120
Study 26727778 — intervention group
Group type: COMPARATOR
Intervention: Control group (clearance of osteophyte in the posterior condyle)
Number of subjects: 120
Study 24098692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills (OCPs)
Number of subjects: 0
Study 24098692 — intervention group
Group type: COMPARATOR
Intervention: Condoms only
Number of subjects: 0
Study 24098692 — intervention group
Group type: COMPARATOR
Intervention: Injectable
Number of subjects: 0
Study 24098692 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine device (IUD)
Number of subjects: 0
Study 24098692 — intervention group
Group type: COMPARATOR
Intervention: Contraceptive implant
Number of subjects: 0
Study 24098692 — intervention group
Group type: COMPARATOR
Intervention: Tubal ligation
Number of subjects: 0
Study 22340793 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure therapy from -19 kPa to -8 kPa, n = 10
Number of subjects: 20
Study 22340793 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure therapy, n = 10
Number of subjects: 20
Study 22340793 — intervention group
Group type: COMPARATOR
Intervention: Control group (covered with petrolatum gauze overlaid with saline gauze and dry gauze), n = 10
Number of subjects: 20
Study 19341912 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme (hemoglobin-based oxygen carrier)
Number of subjects: 0
Study 19341912 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (stored red blood cells)
Number of subjects: 0
Study 19341912 — intervention group
Group type: EXPERIMENTAL
Intervention: PolyHeme
Number of subjects: 0
Study 19341912 — intervention group
Group type: COMPARATOR
Intervention: Control (blood)
Number of subjects: 0
Study 17099388 — intervention group
Group type: EXPERIMENTAL
Intervention: comfilcon A lens
Number of subjects: 20
Study 17099388 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrafilcon A lens
Number of subjects: 20
Study 17099388 — intervention group
Group type: COMPARATOR
Intervention: no lens (control)
Number of subjects: 20
Study 15651517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 ug
Number of subjects: 45
Study 15651517 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 3 mg
Number of subjects: 45
Study 15651517 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 20 cc (placebo)
Number of subjects: 45
Study 17953074 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of gerontological nursing
Number of subjects: 130
Study 17953074 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics and education
Number of subjects: 130
Study 17953074 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with elders in family
Number of subjects: 130
Study 17953074 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational background
Number of subjects: 130
Study 17953074 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education needs
Number of subjects: 130
Study 17953074 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing education model
Number of subjects: 130
Study 10965244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-mm Acrysof lens implants through 3.2-mm outer and 4-mm inner temporal clear corneal openings (stretch incision)
Number of subjects: 147
Study 10965244 — intervention group
Group type: COMPARATOR
Intervention: 5-mm PMMA lenses through temporal clear corneal incisions of 4.1-mm outer and 6.5-mm inner diameter incisions
Number of subjects: 147
Study 10965244 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.5-mm Acrysof lens implants
Number of subjects: 147
Study 10965244 — intervention group
Group type: COMPARATOR
Intervention: 5-mm PMMA lenses
Number of subjects: 147
Study 8986972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl (C)
Number of subjects: 36
Study 8986972 — intervention group
Group type: COMPARATOR
Intervention: Bolus dosing of fentanyl (B)
Number of subjects: 36
Study 8986972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl (C) in phase 2
Number of subjects: 36
Study 8986972 — intervention group
Group type: COMPARATOR
Intervention: Bolus dosing of fentanyl (B) in phase 2
Number of subjects: 36
Study 8986972 — intervention group
Group type: EXPERIMENTAL
Intervention: Both C and B
Number of subjects: 36
Study 1618662 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/RT (three cycles of cis‐platinum and 5‐FU chemotherapy followed by postoperative radiotherapy)
Number of subjects: 442
Study 1618662 — intervention group
Group type: COMPARATOR
Intervention: RT (postoperative radiotherapy alone)
Number of subjects: 442
Study 1618662 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/RT
Number of subjects: 442
Study 1618662 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 442
Study 6208728 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic cream with an eutectic mixture of 5% lidocaine and 5% prilocaine applied for 5-15 min.
Number of subjects: 0
Study 6208728 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic cream with an eutectic mixture of 5% lidocaine and 5% prilocaine applied for 30-60 min.
Number of subjects: 0
Study 30929015 — intervention group
Group type: EXPERIMENTAL
Intervention: LCARES intervention group (culturally linguistically targeted Spanish-language fotonovela booklet and DVD plus FIT)
Number of subjects: 76
Study 30929015 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (non-targeted standard Spanish-language booklet plus FIT)
Number of subjects: 76
Study 29624523 — intervention group
Group type: EXPERIMENTAL
Intervention: PP-based intervention with booster sessions
Number of subjects: 128
Study 29624523 — intervention group
Group type: EXPERIMENTAL
Intervention: PP-based intervention with motivational interviewing
Number of subjects: 128
Study 29624523 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly PP exercises
Number of subjects: 128
Study 26639986 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Infiltration Analgesia (LIA)
Number of subjects: 45
Study 26639986 — intervention group
Group type: COMPARATOR
Intervention: Continuous Femoral Nerve Block (FNB)
Number of subjects: 45
Study 25058250 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pleural suction (Group 1)
Number of subjects: 110
Study 25058250 — intervention group
Group type: COMPARATOR
Intervention: No suction (Group 2)
Number of subjects: 110
Study 23041996 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (CAD/CAM system A)
Number of subjects: 10
Study 23041996 — intervention group
Group type: COMPARATOR
Intervention: Group B (CAD/CAM system B)
Number of subjects: 10
Study 19832866 — intervention group
Group type: EXPERIMENTAL
Intervention: Fissurectomy combined with Botulinum Toxin A (80 U of Dysport)
Number of subjects: 21
Study 17686672 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon treatment for further 16‐36 weeks (mean 23.7 weeks) after pegylated interferon + ribavirin treatment cessation.
Number of subjects: 15
Study 17686672 — intervention group
Group type: COMPARATOR
Intervention: Pegylated interferon + ribavirin treatment (before cessation).
Number of subjects: 15
Study 17686672 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural interferon treatment.
Number of subjects: 15
Study 15716195 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL flexible cystoscopy
Number of subjects: 45
Study 15716195 — intervention group
Group type: EXPERIMENTAL
Intervention: HAL rigid cystoscopy
Number of subjects: 45
Study 15716195 — intervention group
Group type: COMPARATOR
Intervention: Standard flexible cystoscopy
Number of subjects: 45
Study 15716195 — intervention group
Group type: COMPARATOR
Intervention: Standard white light rigid cystoscopy
Number of subjects: 45
Study 12079730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (300 mg/day)
Number of subjects: 32
Study 9534512 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 12
Study 8553816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hook pins
Number of subjects: 222
Study 8553816 — intervention group
Group type: COMPARATOR
Intervention: Sliding screw plate
Number of subjects: 222
Study 2234803 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 2234803 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 0
Study 2234803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvants)
Number of subjects: 0
Study 31796467 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel screening program for gastric cancer using serologic tests of Helicobacter pylori antibodies and pepsinogens, and positive family history of gastric cancer in first‐degree relatives (FDR).
Number of subjects: 7773
Study 31796467 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel screening program for gastric cancer.
Number of subjects: 7773
Study 31073737 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 111
Study 31073737 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% glucose solution)
Number of subjects: 111
Study 29284453 — intervention group
Group type: EXPERIMENTAL
Intervention: ST segment analysis (STan) monitoring as an adjunct to cardiotocography (CTG)
Number of subjects: 0
Study 29284453 — intervention group
Group type: COMPARATOR
Intervention: Cardiotocography (CTG) alone
Number of subjects: 0
Study 26024297 — intervention group
Group type: EXPERIMENTAL
Intervention: Blueberry smoothie (twice daily for six weeks)
Number of subjects: 44
Study 26024297 — intervention group
Group type: COMPARATOR
Intervention: Placebo smoothie (twice daily for six weeks)
Number of subjects: 44
Study 24114614 — intervention group
Group type: EXPERIMENTAL
Intervention: Stranger Safety DVD (The Safe Side, 2004) and parent training of abduction-prevention skills
Number of subjects: 0
Study 24114614 — intervention group
Group type: EXPERIMENTAL
Intervention: In situ training from parents
Number of subjects: 0
Study 24114614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 0
Study 22260080 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with tonsil ablation
Number of subjects: 70
Study 22260080 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy with partial tonsillectomy
Number of subjects: 70
Study 22260080 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study 19308718 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV uninfected women
Number of subjects: 1686
Study 19308718 — intervention group
Group type: COMPARATOR
Intervention: HIV infected women
Number of subjects: 1686
Study 19308718 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pregnancy rate
Number of subjects: 1686
Study 16891677 — intervention group
Group type: EXPERIMENTAL
Intervention: Compact fluorescent lamp (CFL) phototherapy
Number of subjects: 100
Study 16891677 — intervention group
Group type: COMPARATOR
Intervention: Standard-length tube lights (STL) phototherapy
Number of subjects: 100
Study 16891677 — intervention group
Group type: EXPERIMENTAL
Intervention: CFL phototherapy
Number of subjects: 100
Study 16891677 — intervention group
Group type: COMPARATOR
Intervention: STL phototherapy
Number of subjects: 100
Study 15617954 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 150 mg/d
Number of subjects: 393
Study 15617954 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 300 mg/d
Number of subjects: 393
Study 15617954 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone 600 mg/d
Number of subjects: 393
Study 15617954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study 11292472 — intervention group
Group type: EXPERIMENTAL
Intervention: Media campaign to increase knowledge about emergency contraception
Number of subjects: 0
Study 9239526 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel therapy at a dose of 175 mg/m2
Number of subjects: 23
Study 9239526 — intervention group
Group type: COMPARATOR
Intervention: Pretreatment with potentially neurotoxic drugs (cisplatin and carboplatin)
Number of subjects: 23
Study 8108224 — intervention group
Group type: EXPERIMENTAL
Intervention: HbOC-DTP combined vaccine
Number of subjects: 6644
Study 8108224 — intervention group
Group type: COMPARATOR
Intervention: Separate injections of HbOC and DTP vaccines
Number of subjects: 6644
Study 2888477 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 2888477 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 0
Study 2888477 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 0